Fig. 6: Antiviral activity of plitidepsin against other viruses.
A Dose-response curve for the anti-MERS-CoV activity (red lines) and cytotoxicity of plitidepsin (gray lines) shown as the mean and S.D. of n exp = 3 and n rep = 9 measured 3 days post-infection. B Dose-response curve for the anti-HCV replicon activity (red lines) and cytotoxicity of plitidepsin (gray lines) shown as the mean and S.D. of n exp = 3 measured 2 days post-infection. C Dose-response curve for the anti-ZIKV activity (red lines) and cytotoxicity of plitidepsin (gray lines) shown as the mean and S.D. of n exp = 3 measured 5 days post-infection. D Dose-response curve for the anti-HSV activity (red lines) and cytotoxicity of plitidepsin (gray lines) shown as the mean and S.D. of n exp = 3 measured 2 days post-infection. E Dose-response curve for the anti-RSV activity (red lines) and cytotoxicity of plitidepsin (gray lines) shown as mean and S.D. of n exp = 3 and n rep = 9 measured 3 days post-infection. F Dose-response curve for the anti-HIV-1 activity (red lines) and cytotoxicity of plitidepsin (gray lines) shown as the mean and S.D. of n exp = 3 measured 5 days post-infection. A–F The IC50 value is also indicated. MERS-CoV Middle East respiratory syndrome coronavirus, HCV hepatitis C virus, ZIKV Zika virus, HSV herpes simplex virus, RSV respiratory syncytial virus, HIV-1 human immunodeficiency virus type 1. Source Data file provides source data.
